MedTrace Logo

Comparison of Aripiprazole Versus Risperidone on Brain Morphology Using MRI

NCT02334904 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 60

Last updated 2016-06-01

No results posted yet for this study

Summary

Significant changes in brain morphology are observed in people with first-episode psychosis. Studies have shown that total brain volume and particular brain structures are decreased in people with psychosis disorders. Recent evidence suggests that some atypical antipsychotic drugs can maintain or increase brain volumes. Thus, we plan to use MRI scans to measure changes in brain morphology in subjects recently diagnosed with bipolar or psychosis disorders who are taking the atypical antipsychotic drugs aripiprazole or risperidone. Secondary objectives include taking blood samples for fasting metabolic indices and neuropsychiatric measures for comparisons between drug treatments.

Conditions

Interventions

DRUG

Aripiprazole

To be prescribed and monitored by participant's attending physician (not given to participants as a part of the study)

DRUG

Risperidone

To be prescribed and monitored by participant's attending physician (not given to participants as a part of the study).

Sponsors & Collaborators

  • Vancouver Coastal Health

    collaborator OTHER_GOV

  • University of British Columbia

    lead OTHER

Principal Investigators

  • Alasdair M Barr, Ph.D · University of British Columbia

  • Lili Kopala, M.D. · University of British Columbia

Eligibility

Min Age
12 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2014-07-31
Primary Completion
2016-06-30
Completion
2016-06-30

Countries

  • Canada

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02334904 on ClinicalTrials.gov